Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATON NYSE:NKGN NASDAQ:OBSV NASDAQ:SCNI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATONPortage Biotech$0.33+3.8%$0.34$0.28▼$13.80$7.78M0.493.17 million shs9.78 million shsNKGNNKGen Biotech$0.06-20.0%$0.09$0.00▼$0.46$7.84M0.664,082 shs105 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs2,060 shsSCNIScinai Immunotherapeutics$0.55+6.6%$0.65$0.45▼$6.18$1.93M2.192.33 million shs60,457 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATONPortage Biotech0.00%0.00%+7.27%-38.52%+33,199,900.00%NKGNNKGen Biotech-6.25%+25.00%+25.00%+25.00%-56.14%OBSVObsEva0.00%0.00%0.00%-80.20%-50.00%SCNIScinai Immunotherapeutics-9.76%-27.83%-11.76%-35.89%-80.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATONPortage Biotech$0.33+3.8%$0.34$0.28▼$13.80$7.78M0.493.17 million shs9.78 million shsNKGNNKGen Biotech$0.06-20.0%$0.09$0.00▼$0.46$7.84M0.664,082 shs105 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs2,060 shsSCNIScinai Immunotherapeutics$0.55+6.6%$0.65$0.45▼$6.18$1.93M2.192.33 million shs60,457 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATONPortage Biotech0.00%0.00%+7.27%-38.52%+33,199,900.00%NKGNNKGen Biotech-6.25%+25.00%+25.00%+25.00%-56.14%OBSVObsEva0.00%0.00%0.00%-80.20%-50.00%SCNIScinai Immunotherapeutics-9.76%-27.83%-11.76%-35.89%-80.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATONPortage Biotech 2.00Hold$2.00502.41% UpsideNKGNNKGen Biotech 0.00N/AN/AN/AOBSVObsEva 0.00N/AN/AN/ASCNIScinai Immunotherapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SCNI, OBSV, NKGN, and ATON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026SCNIScinai Immunotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)2/24/2026ATONPortage Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$2.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATONPortage BiotechN/AN/AN/AN/A($0.79) per shareN/ANKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/AOBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/ASCNIScinai Immunotherapeutics$1.31M1.48N/AN/A$0.78 per share0.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATONPortage Biotech-$6.77M-$8.18N/AN/AN/AN/AN/AN/AN/ANKGNNKGen Biotech-$82.94M-$1.51N/AN/AN/AN/AN/A-479.36%N/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/ASCNIScinai Immunotherapeutics-$8.31M-$9.57N/AN/AN/AN/AN/AN/A7/7/2026 (Estimated)Latest SCNI, OBSV, NKGN, and ATON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2026Q4 2025SCNIScinai ImmunotherapeuticsN/A$3.80N/A$3.80N/A$0.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATONPortage BiotechN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ASCNIScinai ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATONPortage BiotechN/A0.880.88NKGNNKGen BiotechN/A0.020.02OBSVObsEvaN/A0.610.61SCNIScinai Immunotherapeutics0.121.301.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATONPortage Biotech13.36%NKGNNKGen Biotech76.17%OBSVObsEva17.52%SCNIScinai Immunotherapeutics58.41%Insider OwnershipCompanyInsider OwnershipATONPortage BiotechN/ANKGNNKGen Biotech10.36%OBSVObsEva14.40%SCNIScinai Immunotherapeutics6.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATONPortage Biotech623.44 millionN/AN/ANKGNNKGen BiotechN/A130.60 million40.29 millionNot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionableSCNIScinai Immunotherapeutics203.54 million3.32 millionNot OptionableSCNI, OBSV, NKGN, and ATON HeadlinesRecent News About These CompaniesScinai Immunotherapeutics (NASDAQ:SCNI) Shares Down 9.8% - What's Next?May 12 at 2:16 AM | americanbankingnews.comScinai Immunotherapeutics Announces $2.61 Million Private Placement FinancingApril 24, 2026 | prnewswire.comScinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 PrioritiesApril 6, 2026 | prnewswire.comScinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm CollaborationApril 1, 2026 | prnewswire.comScinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026March 19, 2026 | prnewswire.comScinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid PriceMarch 16, 2026 | prnewswire.comScinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of ConceptMarch 2, 2026 | prnewswire.comScinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish PlatformFebruary 25, 2026 | prnewswire.comScinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with RecipharmFebruary 17, 2026 | prnewswire.comScinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthILJanuary 7, 2026 | prnewswire.comScinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short InterestJanuary 2, 2026 | defenseworld.netDScinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline AdvancesDecember 2, 2025 | prnewswire.comScinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO CapabilitiesOctober 6, 2025 | prnewswire.comScinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance SheetSeptember 2, 2025 | prnewswire.comScinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TENJuly 29, 2025 | prnewswire.comScinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025June 12, 2025 | prnewswire.comScinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.June 5, 2025 | prnewswire.comScinai Immunotherapeutics Reports Strong CDMO GrowthJune 2, 2025 | tipranks.comScinai Immunotherapeutics Ltd.: Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash BurnMay 30, 2025 | finanznachrichten.deScinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash BurnMay 30, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCNI, OBSV, NKGN, and ATON Company DescriptionsPortage Biotech NASDAQ:ATON$0.33 +0.01 (+3.75%) Closing price 04/20/2026Extended Trading$0.33 0.00 (0.00%) As of 04/20/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.NKGen Biotech NYSE:NKGN$0.06 -0.02 (-20.00%) As of 10:06 AM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Scinai Immunotherapeutics NASDAQ:SCNI$0.55 +0.03 (+6.56%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
